Abstract
Exogenous surfactant therapy has been widely studied in acute respiratory distress syndrome (ARDS) but has failed to show mortality benefit in several trials. The COVID-19 pandemic has renewed interest in exogenous surfactant, and clinical trials are investigating surfactant therapy in COVID-19 respiratory disease. There is biological plausibility of benefit from surfactant, and patients who are early in their disease and do not meet full ARDS diagnostic criteria may respond differently, and perhaps more favourably, to surfactant therapy. Clinical trials that investigate patients with severe ARDS have a high likelihood of reproducing already known findings of surfactant therapy and systematically exclude patients who might exhibit a novel response to exogenous surfactant.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
